UBS Group AG Boosts Stock Holdings in Precigen, Inc. $PGEN

UBS Group AG grew its position in shares of Precigen, Inc. (NASDAQ:PGEN) by 41.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 891,428 shares of the biotechnology company’s stock after purchasing an additional 260,824 shares during the quarter. UBS Group AG owned approximately 0.25% of Precigen worth $3,726,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Precigen by 7.7% in the 2nd quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company’s stock worth $5,325,000 after acquiring an additional 269,580 shares in the last quarter. Bank of America Corp DE increased its holdings in Precigen by 201.1% in the 3rd quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after acquiring an additional 1,673,731 shares in the last quarter. Parkman Healthcare Partners LLC increased its holdings in Precigen by 36.2% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,101,715 shares of the biotechnology company’s stock worth $6,915,000 after acquiring an additional 558,892 shares in the last quarter. Boxer Capital Management LLC purchased a new stake in Precigen in the 3rd quarter worth $2,796,000. Finally, Millennium Management LLC increased its holdings in Precigen by 226.5% in the 3rd quarter. Millennium Management LLC now owns 779,558 shares of the biotechnology company’s stock worth $2,565,000 after acquiring an additional 540,806 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Trading Down 0.9%

Shares of PGEN stock opened at $4.24 on Friday. The company’s 50-day moving average price is $3.93 and its 200-day moving average price is $4.08. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -3.59 and a beta of 1.07. Precigen, Inc. has a twelve month low of $1.28 and a twelve month high of $5.47.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The company had revenue of $23.25 million for the quarter, compared to analysts’ expectations of $20.81 million. As a group, equities analysts predict that Precigen, Inc. will post 0.04 earnings per share for the current year.

Analysts Set New Price Targets

PGEN has been the subject of several recent analyst reports. HC Wainwright boosted their price target on shares of Precigen from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Citizens Jmp upped their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. Finally, Wall Street Zen raised shares of Precigen from a “hold” rating to a “buy” rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Precigen currently has a consensus rating of “Hold” and an average price target of $11.00.

Insider Buying and Selling at Precigen

In related news, Director Randal J. Kirk sold 4,772,781 shares of the stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $3.30, for a total transaction of $15,750,177.30. Following the completion of the transaction, the director owned 302,213 shares of the company’s stock, valued at approximately $997,302.90. This trade represents a 94.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 47.10% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.